Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Monday morning,Benzinga reports. The firm currently has a $400.00 price target on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other reports. Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Raymond James increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Stock Up 4.4 %

Shares of NASDAQ:ALNY opened at $251.01 on Monday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The business has a fifty day simple moving average of $248.15 and a 200 day simple moving average of $259.81. The firm has a market cap of $32.38 billion, a P/E ratio of -95.81 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the firm posted $1.15 EPS. The business’s quarterly revenue was down 33.3% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Eventide Asset Management LLC lifted its stake in Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the period. AQR Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 92.5% in the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after acquiring an additional 130,482 shares during the period. Deerfield Management Company L.P. Series C purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $29,111,000. Finally, Avoro Capital Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.